GRFS logo

GRIFOLS SA-ADR

GRFSNASDAQ
πŸ† #1154 by market capEarnings Feb 24 Β· PostUS Equity
$329.59β–² $21.46 (+6.51%)
Simulated price
πŸ””
Track GRFS
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 6.5%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$6.22B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+0.2%
Slowing
πŸ“ŠGross Margin
37.2%
Healthy
πŸ’΅FCF Margin
10.3%
Healthy
βš–οΈP/S Ratio
0.9x
Cheap
Otter Score
76
Good
No chart data available for GRFS.

Trading Snapshot

Day Range
$326.90 – $332.80
52-Week Range
$6.96 – $10.23
Volume
$3.76B
Avg Volume
$3.88B
Shares Outstanding
846.0M
Next Earnings
Nov 8, 2026

Fundamentals Snapshot

Annual Revenue
$7.23B
Last Q Revenue
$1.87B
P/E Ratio
14.3
P/S Ratio
0.9x
EPS (TTM)
$0.66
Dividend Yield
0.86%
Dilution (1yr)
+0.0%

Why Investors Own GRFS

  • βœ“High-growth profile β€” revenue up +16.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 70% gross margin and 8% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

GRFS logo

GRIFOLS SA-ADR

GRFS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$7.2Bβ–² +0.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
35.7%β–Ό βˆ’7.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$1.2Bβ–Ό βˆ’0.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$751Mβ–² +41.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
680.6Mβ–² +0.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$7.9Bβ–² +$1.2B YoY
StockOtter Β· stockotter.space

About GRIFOLS SA-ADR

Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
76/100

Analyst Ratings

β“˜
Consensus
Buy
21 analysts
Strong Buy5
Buy9
Hold5
Sell2
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates